Agena Bioscience Granted EUA for High-Throughput, Low-Cost SARS-CoV-2 Panel
The Pharma Data
OCTOBER 27, 2020
Food and Drug Administration (FDA). ” With the panel’s authorization, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or reagent availability. SAN DIEGO , Oct.
52 
Let's personalize your content